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Abstract
Kidney disease is a recognised risk factor for poor COVID-19 outcomes. Up to 30 June
2020, the UK Renal Registry (UKRR) collected data for 2,385 in-centre haemodialysis
(ICHD) patients with COVID-19 in England and Wales. Overall unadjusted survival at 1
week after date of positive COVID-19 test was 87.5% (95% CI 86.1–88.8%); mortality
increased with age, treatment vintage and there was borderline evidence of Asian ethnicity
(HR 1.16, 95% CI 0.94–1.44) being associated with higher mortality. Compared to the gen-
eral population, the relative risk of mortality for ICHD patients with COVID-19 was 45.4 and
highest in younger adults. This retrospective cohort study based on UKRR data supports
efforts to protect this vulnerable patient group.
Introduction
Coronaviruses (CoVs) are important pathogens in both humans and other vertebrate animals.
In their reservoirs, CoV infections mainly affect respiratory, gastrointestinal, liver and central
nervous systems [1]. At the end of 2019, a novel coronavirus called Severe Acute Respiratory
Syndrome coronavirus 2 (SARS-CoV-2) started spreading across the world, causing a substan-
tive number of cases. The new infectious disease was named COVID-19.
Current evidence shows that comorbidities, such as diabetes, hypertension and chronic kid-
ney disease, and advanced age, are risk factors associated with worse outcomes from COVID-
19 [2–4]. Children appear to be less affected than adults [5, 6], although coexisting kidney dis-
ease is reported among cases of children requiring intensive care support [7].
A recent meta-analysis reported that patients with COVID-19 developing acute kidney injury
had significant 4-fold increased risk of death than patients without acute kidney injury [8].
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In-centre haemodialysis (ICHD) patients regularly visit hospital for their treatment and are
at especially high risk, not just because of older age, kidney failure and higher frequency of
comorbidities [9], but also because COVID-19 is more likely to spread among hospitalised
patients [10]. Moreover, patients with end-stage kidney disease have impairment in both
innate and adaptive immunity in uremic state with decreased endocytosis, impaired matura-
tion of monocytes and dendritic cells and malfunction of toll-like receptors [11].
The aim of this retrospective cohort study was to describe the features and mortality of
patients on ICHD in England and Wales who had laboratory-confirmed COVID-19.
Methods
On behalf of the Renal Association, the UK Renal Registry (UKRR) collects patient data with-
out consent under section 251 from the Health Research Authority’s Confidentiality Advisory
Group. The data were pseudonymised prior to being analysed. This study was approved by the
North East Newcastle & North Tyneside 1 Research Ethics Committee (16/NE/0042).
Data on ICHD patients with a positive laboratory test for SARS-CoV-2 were collected by
the UK Renal Registry (UKRR) between 26 March and 30 June 2020 using weekly returns
from renal centres in England and Wales about each patient (NHS number, date of birth and
date of positive test). This collection included all paediatric cases and covered the 18-week
period from 3 March to 30 June.
Data were checked and NHS numbers validated, with queries returned to the submitting
centre. Using NHS number and date of birth, the Demographics Batch Service was used to
retrieve sex, postcode and date of death, if applicable, for every patient in England and Wales.
Postcode was used to determine the lower super output area and the associated Index of Multi-
ple Deprivation (IMD) [12].
The Demographics Batch Service is only available in the UK for England and Wales–it was
therefore not possible to include in this analysis data from Northern Ireland and Scotland. In
addition, Scotland only reports aggregated COVID-19 data to the UK Renal Registry (UKRR).
For survival analysis, patients with a test date after 23 June 2020 were excluded to allow for
at least 7 days of follow-up time. Survival time was calculated from the date of positive test to
either the date of death or the end of follow-up (30 June). Kaplan Meier unadjusted survival
and Cox proportional-hazards models were used to describe survival and hazard ratios. The
assumption of proportional hazards was tested and met for the Cox model. To investigate if
vintage (time on renal replacement treatment) was associated with an increased risk of mortal-
ity, vintage was divided into 3 categories: pre-2016, 2016–2018 and 2019 onwards.
Relative risk of death for English ICHD patients by age and English NHS region were calcu-
lated using the England ICHD population (end of 2018, the most recent data available),
England mid-year 2018 general population (based on the 2011 census), England ICHD
COVID-19 deaths (3 March to 30 June) and England general population COVID-19 deaths (3
March to 30 June).
Analyses were performed using SAS version 9.4. Alpha level of 0.05 and two-sided tests
were used throughout.
Results
At the end of 2018, there were 21,509 adult ICHD patients alive in England and Wales.
Between 3 March and 30 June 2020, 50 of 51 renal centres in England and 5 of 5 in Wales
reported 2,385 adult ICHD patients with COVID-19 to the UKRR. London had the highest
percentage of ICHD patients with COVID-19 (18.7%), with a range of 10.4–24.0% among its 7
renal centres. The remaining regions ranged from 3.5%–12.2% of ICHD patients with
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COVID-19. Three COVID-19 cases in ICHD patients aged<18 years were reported from a
prevalent paediatric ICHD cohort of 116 (2.6%).
Among adults, most patients with COVID-19 were aged 60–79 years (50.8%) and 18.5% were
aged�80 years. 62.6% were male, which was just above the proportion of ICHD male patients in
the UK (61.8%). A similar proportion of patients that tested positive for SARS-CoV-2 were from
ethnic minorities (15.2% were Asian and 11.6% were Black), compared to the overall ICHD popu-
lation in England and Wales (14.7% Asian and 11.9% Black, respectively) (Table 1).
Survival (unadjusted) at 1 week from the date of a positive SARS-CoV-2 test was 87.5%
(95% CI 86.1–88.8%) and 80.0% at 2 weeks (95% CI 78.3–81.5%) (Fig 1).
There were no deaths in children. Patients on ICHD with COVID-19 aged�80 years had a
mortality risk of about 4.2 times that of those aged 18–59 years (Table 2). There was weak evi-
dence of males with COVID-19 on ICHD doing worse than females (HR 1.19, 95% CI 1.01–
1.40). Asian patients on ICHD with COVID-19 had a borderline 16% higher mortality risk
than White patients, with no difference seen between Black and White patients. Deprivation
was not associated with mortality on ICHD and no interactions were observed. Patients on
renal replacement treatment for more than 5 years had a 42% higher mortality risk compared
to patients who started dialysis during the last year.
Compared to the general population in England with COVID-19, the relative risk of death
in English ICHD patients with COVID-19 was 45.4 (95% CI 41.9–49.1), and decreased with
age from a peak in the 20–39 years age group to 9.8 times the risk of death in the general popu-
lation at�80 years (Table 3), with a high interregional variability.
Discussion
The relative risk of death associated with COVID-19 among ICHD patients was much higher
than that of the general population in England, especially among those of younger age. So far,
Table 1. Demographic comparison between adult patients on ICHD in England and Wales at the end of 2018 and
adult patients on ICHD in England and Wales with COVID-19 from 3 March to 23 June 2020.
Variable ICHD adults end 2018 (n = 21,509)a ICHD adults with COVID-19b (n = 2,385)c
Age, y
Median (IQR) 67 (55–77) 68 (55–77)
18–39 (%) 7 5
40–59 (%) 27 26
60–79 (%) 48 51
�80 (%) 18 18






Most deprived quintile (%) 30 31
ICHD, in-centre haemodialysis
aPercentages exclude missing data: there were 3% of patients with missing ethnicity and <1% with missing
deprivation.
bFor UK renal centres that submitted patients with COVID-19 to the UKRR.
cPercentages exclude missing data: there were 3% with missing ethnicity and 1% with missing deprivation.
dExcluded 3 patients aged <18 and 9 patients without at least 1 week follow-up.
https://doi.org/10.1371/journal.pone.0241263.t001
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Fig 1. Kaplan Meier unadjusted survival for Sars-CoV-2 positive patients—2-week survival.
https://doi.org/10.1371/journal.pone.0241263.g001
Table 2. Multivariable analysis of time to death amongst ICHD adult patients in England and Wales with COVID-19 positive test results, 3 March to 30 June 2020.
Variable No. of patients No. of deaths Hazard ratio 95% CI
Age, y
18–59 718 86 1.00
60–79 1,190 340 2.57 2.03–3.26
�80 428 187 4.24 3.28–5.49
Sex
Male 1,461 398 1.19 1.01–1.40
Female 875 215 1.00
Ethnicity
White 1,638 424 1.00
Asian 353 107 1.16 0.94–1.44
Black 277 60 0.86 0.65–1.14
Other 68 22 1.36 0.89–2.10
Vintage
<2016 887 276 1.42 1.15–1.75
2016–18 788 196 1.12 0.90–1.39
�2019 661 141 1.00
aAll variables in the table were mutually adjusted for each other.
bPatients with missing ethnicity data were excluded n = 49.
https://doi.org/10.1371/journal.pone.0241263.t002
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and in contrast to the adult population, no deaths have been reported in paediatric patients
aged<18 years. There was borderline evidence both for males with COVID-19 on ICHD
doing worse than females and Asian patients having a 16% higher mortality than White
patients.
As observed in other countries, to now, most deaths in the UK have been in people aged
�50 years, with 55% of these males [13]. Data from the UK Intensive Care National Audit and
Research Centre, indicate that among patients with COVID-19 admitted to intensive care,
1.7% had a history of kidney replacement therapy, 70.3% were male and there was an over-
representation of those of Asian and Black ethnicities [14], similar to what we report for the
ICHD population.
ICHD increases the risk of transmission of infection among patients and the high relative
risk of death among younger individuals with COVID-19 on ICHD highlights their extreme
vulnerability.
Despite level of deprivation correlating to the percentage of ICHD patients with COVID-
19, deprivation was not a major predictor of mortality from COVID-19 on ICHD.
Previous studies have demonstrated the effects of length of time spent on dialysis treatment
(vintage) on mortality, concluding that prolonged dialysis increases the mortality risk of
patients receiving haemodialysis [15, 16]. A few studies have also shown the specific associa-
tion between length of time on dialysis and higher risk for infection-related mortality [17, 18].
Moreover, a recent retrospective cohort study in a single centre in Spain analysed the clini-
cal course and outcomes of 36 maintenance haemodialysis patients hospitalised with COVID-
19 during the period March to April 2020. The authors concluded that none of the classical
cardiovascular risk factors in the general population were associated with higher mortality,
and that compared to survivors, non-survivors had significantly longer dialysis vintages [19].
In line with these results, in our study we found a positive association between treatment vin-
tage and survival of ICHD patients with COVID-19.
Table 3. Relative risk of death for ICHD patients with COVID-19 by age group and NHS region in England.
Variable England COVID-19 death rate per
10,000a







20–39 0.1 60.5 432 213.4–
873
40–59 1.5 143.4 94.1 75.1–118
60–79 10.5 346.9 33.1 29.7–36.9
�80 55.7 548.5 9.8 8.5–11.3
Region
East of England 5.4 253.2 46.7 33.5–65.2
London 6.9 433.3 63.2 55.8–71.7
Midlands 5.4 293.7 54.6 45.7–65.2
North East &
Yorkshire
5.2 267.7 51.5 40.9–65
North West 6.5 223.7 34.5 26.1–45.8
South East 3.7 276.5 73.9 57.3–95.2
South West 2.3 130.6 57.7 36.8–90.5
ICHD, in-centre haemodialysis
aNumber of deaths recorded 3 March to 30 June 2020 in England divided by the England mid-2018 population estimate.
bNumber of deaths recorded 3 March to 30 June 2020 in the English ICHD population divided by the end-2018 prevalent English ICHD population.
https://doi.org/10.1371/journal.pone.0241263.t003
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To better understand the potentially higher mortality from COVID-19 seen for the Asian
group, but not in the Black group, other factors such as comorbidities and their effect on sur-
vival of COVID-19 patients should be investigated. People of Asian origin are the UK’s largest
ethnic minority in several cities [20] and type 2 diabetes is up to 6 times more common in
Asian than White people [20, 21], which translates to a higher prevalence of diabetes as a cause
of requiring ICHD [22].
Although the multivariable analysis was controlled for important factors related to the out-
comes, the possibility of residual confounding from unmeasured variables cannot be excluded.
We were unable to adjust for comorbidities and/or biochemical data for which both factors
detailed comparison data for the general population were not available at the time of our
analysis.
Moreover, we could not compare to other treatment modalities, such as peritoneal dialysis
or transplantation, because reporting of COVID-19 in these populations is currently unreliable
but may be better investigated in future thanks to development of further linkage of UKRR
dataset to the national test result data. Data on mortality in ICHD patients as a result of causes
not directly related to COVID-19 were not available, but in the future will explain the real bur-
den of mortality associated with COVID-19 among ICHD patients in the UK.
Conclusions
Despite some limitations, results of this study show the extremely high relative mortality of
COVID-19 patients on ICHD and are important to support collective efforts to minimise risk
of transmission in this very vulnerable patient group.
Acknowledgments
We thank staff at all adult and paediatric renal centres in the UK who submit data to the
UKRR and who care for kidney patients affected by COVID-19. We are also grateful to the
Renal Association COVID-19 National Renal Data Coordinating Group for their guidance on
this analysis: Paul Cockwell, Ron Cullen, Rachel Gair, Daniel Gale, Matt Graham-Brown,
Thomas Hiemstra, Toby Humphrey, Carol Inward, Rachel Johnson, Graham Lipkin, Fiona
Loud, Stephen Marks, Lisa Mumford, Matthew Robb, Adnan Sharif, Neil Sheerin, Laurie
Tomlinson and Charlie Tomson.
Author Contributions
Conceptualization: Manuela Savino, Retha Steenkamp, Dorothea Nitsch, James Medcalf.
Data curation: Fran Benoy-Deeney, James Griffin, Retha Steenkamp.
Formal analysis: Anna Casula, Shalini Santhakumaran, David Pitcher, Esther Wong, Winnie
Magadi, Retha Steenkamp.
Methodology: Manuela Savino, Anna Casula, Retha Steenkamp, Dorothea Nitsch, James
Medcalf.
Supervision: Retha Steenkamp, Dorothea Nitsch, James Medcalf.
Writing – original draft: Manuela Savino, Anna Casula, Shalini Santhakumaran, David
Pitcher, Esther Wong, Winnie Magadi, Katharine M. Evans, Lucy Plumb, Retha
Steenkamp.
Writing – review & editing: Manuela Savino, Katharine M. Evans, Retha Steenkamp, Dor-
othea Nitsch, James Medcalf.
PLOS ONE Outcomes of haemodialysis patients with COVID-19
PLOS ONE | https://doi.org/10.1371/journal.pone.0241263 October 23, 2020 6 / 8
References
1. Xu J, Zhao S, Teng T, Abdalla AE, Zhu W, Xie L, et al. Systematic comparison of two animal to human
transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses. 2020; 12(2): 244.
2. Wu Z, McGoogan J. Characteristics of and Important Lessons from the Coronavirus Disease 2019
(COVID 2019) Outbreak in China: Summary of a Report of 72,314 Cases from the Chinese Centre for
Disease Control and Prevention. JAMA. 2020; 323(13): 1239–1242. https://doi.org/10.1001/jama.
2020.2648 PMID: 32091533
3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpa-
tients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229): 1054.
https://doi.org/10.1016/S0140-6736(20)30566-3 PMID: 32171076
4. Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. COVID-19 patients’ clinical characteris-
tics, discharge rate, and fatality rate of meta-analysis. J. Med. Virol. Mar 2020. https://doi.org/10.1002/
jmv.25757 PMID: 32162702
5. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis
than adults. Acta Paediatr. Mar 2020. https://doi.org/10.1111/apa.15270 PMID: 32202343
6. Lee PI, Hu YL, Chen PY, Huang YC, Hsueh PR. Are children less susceptible to COVID-19? J. Micro-
biol. Immunol. Feb 2020. https://doi.org/10.1016/j.jmii.2020.02.011 PMID: 32147409
7. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 infection in children. N. Engl. J. Med. Apr
2020. https://doi.org/10.1056/NEJMc2005073 PMID: 32187458
8. Ali H, Daoud A, Mohamed MM, Salim SA, Lenar Yessayan L, Baharani J, et al. Survival rate in acute
kidney injury superimposed COVID-19 patients: a systematic review and meta-analysis. Ren. Fail.
2020; 42(1): 393–7. https://doi.org/10.1080/0886022X.2020.1756323 PMID: 32340507
9. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with Acute Respiratory Distress
Syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA
Inter. Med. May 2020. https://doi.org/10.1016/j.kint.2020.0994
10. Naicker S, Yang CW, Hwang SJ, Liu BC, Chen JH, Jha V. The novel coronavirus 2019 epidemic and
kidneys. Kidney Int. May 2020. https://doi.org/10.1016/j.kint.2020.03.001 PMID: 32204907
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